Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)

Andrea De Giglio, Laura Mezquita, Edouard Auclin, Felix Blanc-Durand, Mariona Riudavets, Caroline Caramella, Gala Martinez, Jose Carlos Benitez, Patricia Martin-Romano, Lamiae El-Amarti, Lizza Hendriks, Roberto Ferrara, Charles Naltet, Pernelle Lavaud, Anas Gazzah, Julien Adam, David Planchard, Nathalie Chaput, Benjamin Besse*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Web of Science)
Original languageEnglish
Article number2827
Number of pages11
JournalCancers
Volume12
Issue number10
DOIs
Publication statusPublished - Oct 2020

Keywords

  • non-small cell lung cancer
  • immunotherapy
  • steroids
  • PEMBROLIZUMAB
  • IMMUNOTHERAPY
  • ASSOCIATION
  • RISK

Cite this